연구
연구업적
최근 5년 연구업적 현황
| 연도 | 2025년 | 2024년 | 2023년 | 2022년 | 2021년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 196편 | 179편 | 173편 | 163편 | 184편 |
| 공동 | 132편 | 147편 | 120편 | 115편 | 136편 | |
| 합계 | 328편 | 326편 | 293편 | 278편 | 320편 | |
1495. An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
Nam SJ1, Go H, Paik JH, Kim TM, Heo DS, Kim CW, Jeon YK.
Leuk Lymphoma
201411,55(11)2466-76
Link
1494. Low-Dose Whole Brain Radiotherapy with Tumor Bed Boost after Methotrexate-Based Chemotherapy for Primary Central Nervous System Lymphoma
Byoung Hyuck Kim, Il Han Kim, Sung-Hye Park, Chul Kee Park, Hee Won Jung, Tae Min Kim, , Se-Hoon Lee, Dae Seog Heo,
Cancer Res Treat 2014; 46(3): 261-269
Link
1493. Immunohistochemical analysis of cyclo- oxygenase-2 and brain fatty acid binding protein expression in grades I-II meningiomas: Correlation with tumor grade and clinical outcome after radiotherapy
Kang HC, Kim IH, Park CI, Park SH
Neuropathology. 2014 Oct;34(5):446-54.
Link
1492. Hypofractionated chemoradiotherapy with temozolomide as a treatment option for glioblastoma patients with poor prognostic features.
Lim YJ, Kim IH, Han TJ, Choi SH, Park SH, Park CK, Paek SH, Lee SH, Kim TM.
Int J Clin Oncol. 2015 Feb;20(1):21-8. doi: 10.1007/s10147-014-0690-6. Epub 2014 Apr 5.
Link
1491. Exclusive radiotherapy for gliomatosis cerebri: long-term follow-up at a single institution.
Kim K, Chie EK, Park HJ, Kim DG, Jung HW, Park SH, Kim IH.
Clin Transl Oncol 2014 Sep;16(9):829-33
Link
1490. Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients.
Koh Y1, Lee SY, Kim I, Kwon JH, Yoon SS, Park S, Chung MH, Suh SY, Kim KS, Kim HS.
Cancer Chemother Pharmacol. 2014 Sep;74(3):653-7. doi: 10.1007/s00280-014-2555-0. Epub 2014 Aug 6.
Link
1489. Enhanced cytotoxic effect of radiation and
temozolomide in malignant glioma cells:
targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases
Eun Jung Choi1†, Bong Jun Cho1†, David J Lee1†, Yeo Hyeon Hwang1†, Sun Ha Chun1, Hans H Kim1
and In Ah Kim1,2
BMC Cancer. 2014 Jan 13;14:17. doi: 10.1186/1471-2407-14-17.
Link
1488. Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
Keam B, Ha H, Kim TM, Jeon YK, Lee SH, Kim DW, Kim CW, Heo DS.
Leuk Lymphoma. 2015 Jan 21:1-7. [Epub ahead of print]
Link
1487. Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Keam B1, Kim DW1, Park JH2, Lee JO2, Kim TM1, Lee SH1, Chung DH3, Heo DS1.
Cancer Res Treat. 2014 Oct;46(4):323-30. doi: 10.4143/crt.2013.120. Epub 2014 Jul 14.
Link
1486. The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer.
Sim SH1, Keam B, Kim DW, Kim TM, Lee SH, Chung DH, Heo DS.
J Cancer Res Clin Oncol. 2014 Dec;140(12):2135-42. doi: 10.1007/s00432-014-1768-2. Epub 2014 Jul 9.
Link